MedTrace Logo

Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

NCT05441904 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-07-01

No results posted yet for this study

Summary

The study was planned in 2 parts: Parts A and B. In Part A, we tested 2 single doses of the study medicine in healthy volunteers: 500 mg and 750 mg. Part B was an optional part to test once-daily doses of the study medicine in healthy volunteers. We aimed to assess the safety, tolerability find out the side effects and blood levels of the PXL770.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

PXL770

A single dose of 500 and 750 mg was administered to each subject.

Sponsors & Collaborators

  • Poxel SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2021-03-29
Completion
2021-03-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05441904 on ClinicalTrials.gov